Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Aug 17, 2026
Revenue (TTM)
$329.43B
+2.1% YoY
Gross margin
82.0%
EPS (latest q)
$0.96
vs $0.82 est · beat
52-wk position
40.9%
-25.8% vs 52w high · -8.8% 1mo
Price (last ~year)
Novo Nordisk shares have declined 8.8% over the past month as management acknowledged competitive pressure in the obesity drug market, despite the company maintaining an 82.0% gross margin and 42.5% operating margin. The firm reported $329.43B in TTM revenue and $20.99B in net income for the quarter ending June 30, 2026. The stock currently trades at a P/E of 11.33 with a market capitalization of $201.05B.
Valuation
- Market cap
- $201.05B
- P/E
- 11.33
- PEG
- 3.138
- P/B
- 5.89
- P/S
- 0.61
- EV/EBITDA
- 9.38
- Beta
- 0.349
- Analyst target
- $47.05
Quality & returns
- Gross margin
- 82.0%
- Operating margin
- 42.5%
- Profit margin
- 35.3%
- ROE
- 59.8%
- ROA
- 18.7%
Price movement
- Last
- $45.89
- 1-month
- -8.8%
- 3-month
- +3.6%
- RSI (14)
- 38
- vs SMA200
- +0.4%
- 52-wk position
- 40.9% -25.8% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $78.49B | $27.06B | $20.99B | $38.68B |
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
Recent news
- Somewhat-Bullish GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) · 2026-08-15
- Neutral Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race · 2026-08-13
- Somewhat-Bullish Obesity not a 'zero-sum game' as patients crave optionality, Novo CEO says: Reuters · 2026-08-13
- Neutral Novo Nordisk CEO Doustdar says obesity drugs market won't be dominated by one player · 2026-08-13
- Neutral Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair' · 2026-08-12
- Neutral Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps · 2026-08-12
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)